Technology News and Research

RSS

JMC launches comprehensive lung cancer program

Recruiting one of the nation's leading specialists in minimally-invasive lung and chest surgery, Jupiter Medical Center (JMC) has launched the first comprehensive program in Palm Beach and Martin counties dedicated to prevention, early detection, treatment and care of patients with lung cancer and other diseases of the chest and lung.

10 Nov 2011

Simple portable test can diagnose 'vegetative' patients with consciousness

The Coma Science Group, led by Dr Steven Laureys, has developed, along with its partners in London, Ontario, (Canada) and Cambridge (England), a portable test which will permit a simpler and less expensive diagnosis of 'vegetative' patients who still have consciousness, despite the fact that they do not have the means to express it.

9 Nov 2011

ACADIA third quarter revenues decrease to $584,000

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

First Edition: November 9, 2011

In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.

9 Nov 2011

Accretive Health third quarter net services revenue increases 38% to $218.9 million

Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services and population health management services infrastructure, today announced financial results for the third quarter ended September 30, 2011.

9 Nov 2011

CU Denver researchers awarded Grand Challenges Explorations grant

The University of Colorado Denver announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

9 Nov 2011

Genetic sequencing key to fundamentally understanding diseases

What started back in 2004 as a three-person start-up may well be on its way to becoming a multi-million euro success story. Advanced by a team of young Dutch scientists pushing disruptive biotech innovations onto the market, the SME FlexGen is attracting the attention of some key investors and demonstrating the added value that public support can offer to innovative SMES, with the Eurostars funding programme leading the way.

9 Nov 2011

BioClinica third quarter service revenues increase 4.1% to $16.6 million

BioClinica, Inc., a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

From Clario 9 Nov 2011

Study explores how telework may impact work exhaustion

If you work from home part of the week as a teleworker, does it help reduce work exhaustion caused by juggling work and family commitments? The answer may depend on the level of conflict you have between work and home and your ability to recharge your batteries adequately, according to Professor Timothy Golden, from the Rensselaer Polytechnic Institute in Troy, NY.

9 Nov 2011

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011

Health insurance exchanges generating controversy, even within GOP

A Wisconsin state senator blocking health care reform implementation in the state is calling on Gov. Scott Walker's administration to return a major federal grant to build information technology infrastructure for new health insurance exchanges. So far, though, it looks like Walker isn't listening. Wisconsin is the last GOP-led state holding onto its Early Innovator grant.

9 Nov 2011

Insmed third quarter revenues decrease to $0.4 million

Insmed Incorporated, a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011.

9 Nov 2011

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011